ONE-P TMS Military Veterans

Phase 2Not Yet RecruitingNCT07777380

Fidel Vila-Rodriguez, MD, PhD, FRCPC, DFAPA50 enrolled

Overview

The aim of this study is to examine the feasibility and tolerability of a one-day protocol of repetitive transcranial magnetic stimulation with D-cycloserine (DCS) as an augmentation strategy in military personnel and veterans who have PTSD.

In this feasibility and tolerability trail, 50 patients with PTSD will be recruited at UBC. Patients will be randomised to receive either aiTBS plus DCS or aiTBS plus placebo DCS. The primary outcome is to evaluate the feasibility and tolerability of active aiTBS plus D-Cycloserine (DCS) versus active aiTBS plus placebo-DCS, using a one-day regimen of 15 treatment sessions, in active military personnel or veterans who suffer PTSD. A secondary aim is to explore preliminary signal of clinical efficacy of active aiTBS plus D-Cycloserine (DCS) on the primary outcome to inform sample size calculation for a definitive trial.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

PTSD - Post Traumatic Stress Disorder

Interventions

D-Cycloserine (DCS)DRUG

Participants randomized to the active treatment arm will receive DCS 125 mg orally, administered as one capsule around one hour before active aiTBS treatment.

PlaceboDRUG

Participants randomized to the placebo arm will receive one matched placebo capsule administered orally at the same time point and according to the same procedures as the active investigational product.

Intermittent Theta Burst Stimulation (iTBS)DEVICE

rTMS will employ the MagPro X100/R30 stimulator (MagVenture, Farum, Denmark) equipped with the B70 coil. A scalp heuristic will be used to localize the treatment site over the right DLPFC by modifying the BeamF3 method to the contralateral side. We have previously reported good congruency between the BeamF3 heuristic method and MRI-guided neuronavigation. Prior to the first treatment, each subject's resting motor threshold (RMT) will first be determined according to published methods. Patients will receive 3 minutes of iTBS every 30 minutes for a total of 15 session over two separate days three weeks apart day of treatment using the following parameters: 50 Hz triplet bursts, 5 bursts per second, 2 s on and 8 s off for 20 trains of 600 pulses, preceded by an introductory 3-train acclimatization titration, at an intensity of 80% of the RMT. The treatment protocol will be repeated 3 weeks after the initial treatment day.

Eligibility

Sex: ALLMin age: 19 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * are outpatients between the ages of 19-60; * are voluntary and competent to consent; * are military personnel or veterans; * have DSM-5 diagnosis of PTSD with a CAPS for DSM-5 (CAPS-5) score ≥ 25; * 17-item Hamilton Depression Rating Scale score ≤ 23; * have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening; * if participating in psychotherapy, must have been in stable treatment for at least 1 month prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study; * able to adhere to the treatment schedule; * Pass the TMS adult safety screening (TASS) questionnaire, and the MRI safety screening. Exclusion Criteria: * have a Severe Substance Use Disorder (except tobacco) within the last three (3) months; * have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump; * have active suicidal intent; * are pregnant; * have a lifetime MINI diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms; * have a MINI diagnosis of OCD, or mood disorder that is assessed by a study investigator to be primary and causing greater impairment than PTSD; * have a diagnosis of any personality disorder, assessed by a study investigator to be primary and causing greater impairment than MDD; * have failed a course of ECT in the current episode or previous episode; * have received rTMS for any previous indication; * have any significant neurological disorder, history of seizure disorder (except those therapeutically induced by ECT), or any significant head trauma with clear radiological evidence of cerebrovascular injury on imaging; * have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed; * clinically significant laboratory abnormality, in the opinion of the one of the principal investigators or study physicians (including but not limited to abnormal blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR)); * currently take more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant due to the potential to limit rTMS efficacy; * currently take dicumarol, gingko biloba, isoniazid, ethionamide, fluphenazine, metrizamide, tramadol, warfarin due to potential interactions with D-Cycloserine; * planned vaccination with Bacille Calmette-Guérin, cholera or typhoid or planned imaging procedure with an injectable die, within one week following the treatment days, due to potential interactions with DCS. * allergy to DCS

Locations (1)

Non-Invasive Neurostimulation Therapies Centre, University of British Columbia

Vancouver, British Columbia, Canada

Outcomes

Primary Outcomes

Feasibility of one-day iTBS+DCS: Enrolment

Enrollment rate: participants enrolled ÷ enrolment target by the end of 1.5 years will be ≥ 70% of the enrollment target.

Time frame: 1.5 years

Feasibility: Adherence

Proportion of randomized participants receiving ≥80% of scheduled iTBS sessions, defined as ≥24 sessions

Time frame: 1.5 years

Feasibility: dropout rates

Percentage of dropout rates attributable to the intervention will be ≤ 10%

Time frame: 1.5 years

Central Contacts

Amanda Ding, BSc

CONTACT

(604)-822-7308 ninet.lab@ubc.ca

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.